Benefits of Scientific Advice for Pharmaceutical Companies
For pharmaceutical companies, the benefit of receiving Scientific Advice is reduced uncertainty in the drug development process. Through the Scientific Advice Program, pharmaceutical companies can receive guidance on what CADTH considers to be complete and relevant evidence for a future formulary review of their product by the CADTH Common Drug Review (CDR) or the CADTH pan-Canadian Oncology Drug Review (pCODR). Formulary reviews are used by the CADTH Canadian Drug Expert Committee and CADTH pCODR Expert Review Committee to make recommendations on the reimbursement of drugs to Canadian publicly funded drug plans (except Quebec). Although recommendations are made by CADTH, final decisions on reimbursement rest with individual jurisdictions.
Pharmaceutical companies also have the opportunity to consider CADTH Scientific Advice in the context of global information and advice. Understanding consistencies and inconsistencies in requirements across health technology assessment agencies internationally may enhance global drug development strategies.
Benefits of Scientific Advice for CADTH, Canadian Decision-Makers, and Patients
For CADTH, the Scientific Advice Program provides an opportunity to influence the evidence generated, potentially leading to more complete and relevant evidence on which to base CADTH recommendations. Stronger recommendations benefit Canadian decision-makers who use the recommendations to create policies related to drug reimbursement, and Canadian patients who are impacted by the policies put in place.
The Scientific Advice Program also provides an opportunity for CADTH to gain early knowledge of new methodologies and approaches on the horizon. This knowledge can be used to better prepare CADTH review teams for the challenges of future drug assessments.